In a groundbreaking advancement in autoimmune treatment, a novel immune reset therapy has led to remission in patients with lupus, a chronic condition affecting over 50,000 individuals in the UK. Early trial data showcases remarkable results, raising hopes for those grappling with this debilitating illness.
Katie Tinkler, one of the first participants in this pivotal trial, expressed her newfound vitality, stating, “I’ve never been this good” since her diagnosis three decades prior. Once bound by her illness and facing challenges like walking her children, Katie is now skiing and free from lupus medication, a transformative change that underscores the potential of this innovative treatment.
Lupus primarily impacts women, with approximately 90% of patients diagnosed in their youth. The disease triggers the immune system to attack healthy tissues, resulting in severe joint pain, skin disorders, and considerable organ damage, particularly to the kidneys. Katie, diagnosed at 20, battled through various stages of the illness, enduring hospitalizations and physical limitations. “Lupus at its worst meant being bedridden, unable to move,” she recounted. But today, as she shares her story, she is filled with energy and enthusiasm for life.
The experimental treatment, developed at University College London Hospitals, employs a revolutionary method to reset malfunctioning immune responses. By instigating a targeted internal conflict among immune cells, the therapy aims to eradicate the rogue B cells that harm the body while allowing healthy ones to flourish. This innovative approach employs genetically modified T cells from the patient's blood, designed to specifically destroy harmful B cells.
For Katie and the other initial patients, the treatment entailed a rigorous process that included chemotherapy to ensure the modified cells would not be rejected. “There were no guarantees it would work; I even had to prepare my GP for the possibility of death,” she revealed.
Having undergone the therapy in November 2024, Katie now enjoys a restored health profile, with her heart, lungs, and kidneys functioning optimally. “I can live to be an old lady with these kidneys that are functioning well. That’s phenomenal,” she noted enthusiastically.
Among the first six participants in the trial, five remain in remission, while one patient has reported improved symptoms despite a flare-up after 11 months. At the recent EULAR European Congress of Rheumatology, researchers indicated that those treated continue to show significant health improvements after 18 months.
Dr. Maria Leandro, a consultant rheumatologist involved in the study, commented, “If we could achieve remission consistently for three to five years, it would signify a major advance in lupus treatment. This is undeniably an exciting step towards a possible cure.” The CAR-T approach, now under consideration for autoimmune diseases, has already found success as an approved therapy for certain blood cancers, including specific leukemias.
The future of lupus treatment may hold unprecedented possibilities, as ongoing studies aim to confirm the longevity of these impressive outcomes and expand access to similar therapies for patients worldwide.
Source: BBC News
Source: BBC News - Health
